STOCK TITAN

DexCom (DXCM) Financials

DXCM NASDAQ
Trailing 12 months to September 30, 2026
Revenue $5.1B +13.0% YoY
Net Income $991.0M +37.5% YoY
EPS (Diluted) $2.54 +41.1% YoY
Free Cash Flow $1.1B +3.4% YoY
Market Cap $30.6B as of Nov 17, 2026
Price / Sales 6.0x on $5.1B revenue, trailing 12 months to September 30, 2026
Price / Earnings 30.9x on $991.0M net income, trailing 12 months to September 30, 2026
Price / Book 12.1x on $2.5B equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Oct 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DXCM SEC filings page.

DexCom, Inc. (DXCM) reported $5.1B in revenue over the twelve months to Sep 30, 2026, up 13.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DXCM FY2025

DexCom's 2025 results show a maturing operating model: revenue growth increasingly converted into profit and cash while leverage fell.

Operating leverage is the central change: revenue rose 15.6% in FY2025 while operating income rose 52.0%, allowing more sales to reach profit. FCF rose 70.8% while capital expenditures rose only 1.3%, indicating the cash improvement was not purchased through proportionally heavier reinvestment.

Gross margin fell 3.1 percentage points to 60.1% over FY2023-FY2025, so the improvement did not come from gross-margin expansion. Operating margin rose 3.1 percentage points to 19.6%, showing that the profit step-up occurred below gross profit through better operating-cost absorption.

Operating cash flow was $1.44B against net income of $836M, so reported earnings translated into cash above the bottom line. Debt-to-equity was 0.5x in FY2025 versus 1.2x in FY2023, showing that stronger retained earnings and balance-sheet repair—not just sales growth—changed the financing profile.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 74 / 100
Financial Health Score 74/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of DexCom, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
79

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. DexCom, Inc. scores 79/100 on it among other operating companies.

Growth
72

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. DexCom, Inc. scores 72/100 on it among other operating companies.

Leverage
72

DexCom, Inc.'s net debt of $323.2M, being $1.2B of long-term debt less $917.7M of cash, came to 0.28 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and DexCom, Inc. scores 72/100 among other operating companies measured the same way.

Liquidity
56

DexCom, Inc. held $1.88 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.88. Liquidity ranks operating companies on that ratio, and DexCom, Inc. scores 56/100 among other operating companies.

Cash Flow
85

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. DexCom, Inc. scores 85/100 on it among other operating companies.

Returns
79

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. DexCom, Inc. scores 79/100 on it among other operating companies.

Altman Z-Score Safe
7.21

DexCom, Inc. scores 7.21, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $30.6B against total liabilities of $3.6B. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong
7/9

DexCom, Inc. passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality Cash-Backed
1.72x

For every $1 of reported earnings, DexCom, Inc. generates $1.72 in operating cash flow ($1.4B OCF vs $836.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe
63.76x

DexCom, Inc. earns $63.76 in operating income for every $1 of interest expense ($911.8M vs $14.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$1.3B
YoY+11.2%
QoQ+2.8%
5Y CAGR+15.6%
10Y CAGR+24.6%

DexCom, Inc. generated $1.3B in revenue in Q3 2026. This represents an increase of 11.2% from the same quarter a year earlier. Against the prior quarter it is up 2.8%.

EBITDA
$401.7M
YoY+31.2%
QoQ+3.9%
5Y CAGR+22.8%

DexCom, Inc.'s EBITDA was $401.7M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 31.2% from the same quarter a year earlier. Against the prior quarter it is up 3.9%.

Net Income
$275.1M
YoY-3.1%
QoQ+10.4%
5Y CAGR+25.8%
10Y CAGRn/m

DexCom, Inc. reported $275.1M in net income in Q3 2026. This represents a decrease of 3.1% from the same quarter a year earlier. Against the prior quarter it is up 10.4%.

EPS (Diluted)
$0.72
YoY+2.9%
QoQ+12.5%

DexCom, Inc. earned $0.72 per diluted share (EPS) in Q3 2026. This represents an increase of 2.9% from the same quarter a year earlier. Against the prior quarter it is up 12.5%.

Cash & Balance Sheet

Free Cash Flow
$272.7M
YoY-52.9%
QoQ+47.8%
5Y CAGR+14.4%
10Y CAGR+44.4%

DexCom, Inc. generated $272.7M in free cash flow in Q3 2026, representing cash available after capex. This represents a decrease of 52.9% from the same quarter a year earlier. Against the prior quarter it is up 47.8%.

Cash & Debt
$961.4M
YoY-47.6%
QoQ-13.0%
5Y CAGR-7.8%
10Y CAGR+25.7%

DexCom, Inc. held $961.4M in cash against $1.2B in long-term debt as of Q3 2026.

Shares Outstanding
373M
YoY-4.4%
QoQ-1.2%

DexCom, Inc. had 373M shares outstanding in Q3 2026. This represents a decrease of 4.4% from the same quarter a year earlier. Against the prior quarter it is down 1.2%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
64.3%
YoY+3.8pp
QoQ+0.9pp
5Y change-4.4pp
10Y change-3.7pp

DexCom, Inc.'s gross margin was 64.3% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 3.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.9 percentage points.

Operating Margin
24.3%
YoY+4.3pp
QoQ0.0pp
5Y change+6.2pp

DexCom, Inc.'s operating margin was 24.3% in Q3 2026, reflecting core business profitability. This is up 4.3 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.

Net Margin
20.5%
YoY-3.0pp
QoQ+1.4pp
5Y change+7.0pp
10Y change+33.1pp

DexCom, Inc.'s net profit margin was 20.5% in Q3 2026, showing the share of revenue converted to profit. This is down 3.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.4 percentage points.

Return on Equity
10.8%
YoY+0.4pp
QoQ+1.3pp
5Y change+6.3pp
10Y change+18.0pp

DexCom, Inc.'s quarterly ROE was 10.8% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.3 percentage points.

Capital Allocation

R&D Spending
$161.6M
YoY+2.6%
QoQ+5.6%
5Y CAGR+4.6%

DexCom, Inc. invested $161.6M in research and development in Q3 2026. This represents an increase of 2.6% from the same quarter a year earlier. Against the prior quarter it is up 5.6%.

Share Buybacks
$400.0M
YoY+113.7%

DexCom, Inc. spent $400.0M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 113.7% from the same quarter a year earlier.

Capital Expenditures
$52.9M
YoY-34.3%
QoQ-37.5%
5Y CAGR-13.3%
10Y CAGR+12.6%

DexCom, Inc. invested $52.9M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 34.3% from the same quarter a year earlier. Against the prior quarter it is down 37.5%.

DXCM Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DXCM quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$1.3B+11.2%$1.3B+13.1%$1.2B+15.0%$1.3B+13.1%$1.2B+21.6%$1.2B+15.2%$1.0B+12.5%$1.1B+7.6%
Cost of Revenue$480.1M+0.5%$478.4M+2.2%$441.6M-1.2%$466.9M+2.0%$477.9M+19.4%$468.3M+24.0%$447.0M+24.5%$457.7M+21.1%
Gross Profit$864.4M+18.2%$830.0M+20.5%$750.3M+27.4%$792.7M+20.9%$731.4M+23.2%$688.8M+9.9%$589.0M+4.8%$655.8M-0.1%
R&D Expenses$161.6M+2.6%$153.0M+3.2%$145.3M+0.1%$148.2M+6.2%$157.5M+16.3%$148.2M+9.0%$145.2M+2.6%$139.5M+2.5%
SG&A Expenses$375.6M+13.3%$358.7M+9.4%$349.7M+12.8%$321.5M-1.8%$331.4M+8.2%$328.0M-1.4%$310.1M-2.9%$327.4M+7.8%
Operating Income$327.2M+34.9%$318.3M+49.7%$255.3M+90.9%$323.0M+71.0%$242.5M+59.5%$212.6M+34.6%$133.7M+32.2%$188.9M-12.9%
EBITDA$401.7M+31.2%$386.5M+40.2%$322.4M+66.4%$388.2M+57.4%$306.1M+47.7%$275.6M+31.2%$193.7M+26.1%$246.7M-8.4%
Interest Expense$2.1M-43.2%$2.2M-42.1%$2.1M-43.2%$3.1M-16.2%$3.7M0.0%$3.8M0.0%$3.7M0.0%$3.7M-5.1%
Income Tax$59.6M-13.0%$68.4M+11.6%$70.0M+43.1%$73.4M+23.2%$68.5M+60.0%$61.3M+38.4%$48.9Mn/m$59.6Mn/m
Net Income$275.1M-3.1%$249.1M+38.5%$199.5M+89.3%$267.3M+76.2%$283.8M+110.8%$179.8M+25.3%$105.4M-28.0%$151.7M-40.8%
EPS (Basic)$0.730.0%$0.65+41.3%$0.52+92.6%$0.69+81.6%$0.73+114.7%$0.46+27.8%$0.27-28.9%$0.38-42.4%
EPS (Diluted)$0.72+2.9%$0.64+42.2%$0.51+88.9%$0.67+76.3%$0.70+105.9%$0.45+28.6%$0.27-25.0%$0.38-37.7%
Diluted Shares (Avg)384M-5.9%390M-4.4%394M-3.4%N/A407M-0.7%408M-2.1%408M-2.2%N/A

DXCM Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DXCM quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$6.2B-16.8%$6.5B-11.9%$6.6B-1.8%$6.3B-2.2%$7.5B+18.0%$7.3B+7.8%$6.8B+4.2%$6.5B+3.5%
Current Assets$3.9B-25.0%$4.1B-18.8%$4.3B-4.9%$4.0B-6.2%$5.2B+22.4%$5.0B+3.7%$4.6B-1.4%$4.3B-2.8%
Cash & Equivalents$961.4M-47.6%$1.1B-4.7%$1.1B+23.6%$917.7M+51.4%$1.8B+195.5%$1.2B+23.4%$904.9M+6.3%$606.1M+7.0%
Short-Term Investments$722.9M-48.7%$704.8M-55.7%$1.1B-30.8%$1.1B-37.6%$1.4B-14.5%$1.6B-21.7%$1.6B-11.9%$1.7B-19.9%
Inventory$770.7M+27.6%$726.4M+27.3%$693.6M+28.9%$629.1M+15.9%$604.1M+3.0%$570.7M+0.1%$538.2M-8.6%$542.6M-3.0%
Accounts Receivable$1.2B+6.9%$1.3B-6.8%$1.1B-5.8%$1.2B+20.9%$1.1B+10.7%$1.3B+42.7%$1.2B+18.0%$1.0B+3.3%
Long-Term Investments$133.6M+75.1%$137.2M-25.0%$212.2M-10.4%$218.0M-12.0%$76.3M-64.9%$182.9M+16.9%$236.8M-14.1%$247.7M+543.4%
Goodwill$24.0M-0.4%$24.1M0.0%$24.2M+4.8%$24.2M+6.1%$24.1M+1.3%$24.1M+3.4%$23.1M-0.4%$22.8M-9.5%
Total Liabilities$3.7B-22.4%$3.8B-19.4%$3.7B-18.0%$3.6B-18.0%$4.8B+9.1%$4.8B+8.9%$4.5B+5.9%$4.4B+4.4%
Current Liabilities$2.3B-32.5%$2.4B-28.7%$2.2B-26.8%$2.1B-26.9%$3.3B+92.3%$3.3B+92.1%$3.0B+90.5%$2.9B+88.4%
Non-Current Liabilities$1.5B+0.9%$1.5B+2.1%$1.5B+0.3%$1.5B+0.1%$1.4B-45.5%$1.4B-45.3%$1.4B-45.2%$1.4B-45.1%
Long-Term Debt$1.2B+0.3%$1.2B+0.3%$1.2B+0.3%$1.2B+0.3%$1.2B-49.2%$1.2B-49.2%$1.2B-49.2%$1.2B-49.2%
Total Equity$2.5B-7.0%$2.6B+1.9%$3.0B+30.5%$2.7B+30.6%$2.7B+37.8%$2.6B+5.7%$2.3B+0.9%$2.1B+1.6%
Retained Earnings$3.2B+45.7%$2.9B+53.1%$2.6B+54.6%$2.4B+52.3%$2.2B+49.8%$1.9B+43.6%$1.7B+45.8%$1.6B+56.4%

DXCM Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DXCM quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$325.6M-50.7%$269.2M-11.2%$525.6M+186.0%$294.0M-2.5%$659.9M+230.8%$303.0M+8.4%$183.8M-12.1%$301.4M+125.6%
Depreciation & Amortization$74.5M+17.1%$68.2M+8.3%$67.1M+11.8%$65.2M+12.8%$63.6M+15.0%$63.0M+20.9%$60.0M+14.3%$57.8M+10.1%
Stock-Based Compensation$36.8M-18.4%$39.0M-13.9%$43.3M+26.6%N/A$45.1M+3.9%$45.3M+1.3%$34.2M-12.3%N/A
Capital Expenditures$52.9M-34.3%$84.7M-10.0%$76.6M-12.0%$101.9M-18.2%$80.5M-27.6%$94.1M+42.4%$87.0M+52.9%$124.6M+137.3%
Free Cash Flow$272.7M-52.9%$184.5M-11.7%$449.0M+363.8%$192.1M+8.7%$579.4M+556.2%$208.9M-2.1%$96.8M-36.4%$176.8M+118.0%
Investing Cash Flow-$76.7M-139.8%$329.8Mn/m-$298.5M-397.9%$306.6Mn/m$192.8M-8.3%-$63.6Mn/m$100.2M+34.0%-$303.7M-173.2%
Financing Cash Flow-$391.5Mn/m-$607.3Mn/m-$25.0M-300.0%-$1.5Bn/m-$175.0Mn/m-$1.7Mn/m$12.5M+166.0%-$1.6Mn/m
Share Buybacks$400.0M+113.7%N/AN/A$312.8Mn/m$187.2M-75.0%N/AN/A$0-100.0%

Not reported in any period shown, so not listed: Dividends Paid.

DXCM Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DXCM quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin64.3%+3.8pp63.4%+3.9pp62.9%+6.1pp62.9%+4.0pp60.5%+0.7pp59.5%-2.9pp56.9%-4.2pp58.9%-4.6pp
Operating Margin24.3%+4.3pp24.3%+6.0pp21.4%+8.5pp25.6%+8.7pp20.1%+4.8pp18.4%+2.6pp12.9%+1.9pp17.0%-4.0pp
Net Margin20.5%-3.0pp19.0%+3.5pp16.7%+6.6pp21.2%+7.6pp23.5%+9.9pp15.5%+1.3pp10.2%-5.7pp13.6%-11.2pp
Return on Equity10.8%+0.4pp9.5%+2.5pp6.8%+2.1pp9.7%+2.5pp10.4%+3.6pp7.0%+1.1pp4.7%-1.9pp7.2%-5.2pp
Return on Assets4.4%+0.6pp3.9%+1.4pp3.0%+1.4pp4.2%+1.9pp3.8%+1.7pp2.5%+0.3pp1.6%-0.7pp2.3%-1.7pp
Current Ratio1.74+0.2x1.73+0.2x1.95+0.4x1.88+0.4x1.56-0.9x1.52-1.3x1.50-1.4x1.47-1.4x
Debt-to-Equity0.490.0x0.470.0x0.42-0.1x0.45-0.1x0.45-0.8x0.48-0.5x0.55-0.5x0.59-0.6x
Liabilities-to-Equity1.46-0.3x1.46-0.4x1.24-0.7x1.31-0.8x1.75-0.5x1.85+0.1x1.98+0.1x2.08+0.1x
Asset Turnover0.22+0.1x0.200.0x0.180.0x0.200.0x0.160.0x0.160.0x0.150.0x0.170.0x
FCF Margin20.3%-27.6pp14.1%-4.0pp37.7%+28.3pp15.3%-0.6pp47.9%+39.0pp18.1%-3.2pp9.3%-7.2pp15.9%+8.0pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
DexCom, Inc. DXCM FY2025 $4.7B $836.3M 17.9% $30.6B 74/100
Koninklijke Philips N.V. PHG FY2025 $20.9B $1.1B 5.0% $29.2B 36/100
STERIS plc STE FY2026 $5.9B $782.3M 13.2% $25.0B 68/100
GE HealthCare Technologies Inc. GEHC FY2025 $20.6B $2.1B 10.1% $37.0B 57/100
Zimmer Biomet Holdings, Inc. ZBH FY2025 $8.2B $705.1M 8.6% $19.3B 60/100
Edwards Lifesciences Corp EW FY2025 $6.1B $1.1B 17.7% $60.6B 72/100

Frequently Asked Questions

DexCom, Inc. (DXCM) reported $4.7B in total revenue for fiscal year 2025. This represents a 15.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

DexCom, Inc. (DXCM) revenue grew by 15.6% year-over-year, from $4.0B to $4.7B in fiscal year 2025.

Yes, DexCom, Inc. (DXCM) reported a net income of $991.0M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $836.3M, with a net profit margin of 17.9%.

DexCom, Inc. (DXCM) reported diluted earnings per share of $2.09 for fiscal year 2025. This represents a 47.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

DexCom, Inc. (DXCM) had EBITDA of $1.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, DexCom, Inc. (DXCM) had $917.7M in cash and equivalents against $1.2B in long-term debt.

DexCom, Inc. (DXCM) had a gross margin of 60.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

DexCom, Inc. (DXCM) had an operating margin of 19.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

DexCom, Inc. (DXCM) had a net profit margin of 17.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

DexCom, Inc. (DXCM) has a return on equity of 30.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

DexCom, Inc. (DXCM) generated $1.1B in free cash flow during fiscal year 2025. This represents a 70.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

DexCom, Inc. (DXCM) generated $1.4B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

DexCom, Inc. (DXCM) had $6.3B in total assets as of fiscal year 2025, including both current and long-term assets.

DexCom, Inc. (DXCM) invested $363.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

DexCom, Inc. (DXCM) invested $599.1M in research and development during fiscal year 2025.

Yes, DexCom, Inc. (DXCM) spent $500.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

DexCom, Inc. (DXCM) had 385M shares outstanding as of fiscal year 2025.

DexCom, Inc. (DXCM) had a current ratio of 1.88 as of fiscal year 2025, which is generally considered healthy.

DexCom, Inc. (DXCM) had a debt-to-equity ratio of 0.45 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

DexCom, Inc. (DXCM) had a liabilities-to-equity ratio of 1.31 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

DexCom, Inc. (DXCM) had a return on assets of 13.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

DexCom, Inc. (DXCM) trades at 30.9x earnings, its market capitalization divided by $991.0M net income, trailing 12 months to September 30, 2026. The market capitalization is $30.6B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

DexCom, Inc. (DXCM) trades at 6.0x sales, its market capitalization divided by $5.1B revenue, trailing 12 months to September 30, 2026. The market capitalization is $30.6B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

DexCom, Inc. (DXCM) has an Altman Z-Score of 7.21, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

DexCom, Inc. (DXCM) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

DexCom, Inc. (DXCM) has an earnings quality ratio of 1.72x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

DexCom, Inc. (DXCM) has an interest coverage ratio of 63.76x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

DexCom, Inc. (DXCM) scores 74 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top